IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm

A securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) for investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges material misstatements regarding the company's lead product Anktiva, including false claims that it is a cancer vaccine and can cure all cancers. The FDA issued a Warning Letter on March 24, 2026, citing inaccurate claims made by the company's Executive Chairman. Following this disclosure, IBRX stock fell 21.12% to $7.42 per share. The deadline to seek lead plaintiff status is May 26, 2026.